The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
The mechanism of action of retigabine (ezogabine), a first‐in‐class K+channel opener for the treatment of epilepsy
Open accessAbstract
Summary: The pharmacologic profile of retigabine [RTG (international nonproprietary name); ezogabine, EZG (U.S. adopted name)], is different from all currently approved antiepileptic drugs (AEDs). Its primary mechanism of action (MoA) as a positive allosteric modulator of KCNQ2–5 (K v 7.2–7.5) ion channels defines RTG/EZG as the first neuronal potassium (K+) channel opener for the treatment of epilepsy. KCNQ2–5 channels are predominantly expressed in neurons and are important determinants of cellular excitability, as indicated by the occurrence of human genetic mutations in KCNQ channels that underlie inheritable disorders including, in the case of KCNQ2/3, the syndrome of benign familial neonatal convulsions. In vitro pharmacologic studies demonstrate that the most potent action of RTG/EZG is at KCNQ2–5 channels, particularly heteromeric KCNQ2/3. Furthermore, mutagenesis and modeling studies have pinpointed the RTG/EZG binding site to a hydrophobic pocket near the channel gate, indicating how RTG/EZG can stabilize the open form of KCNQ2–5 channels; the absence of this site in KCNQ1 also provides a clear explanation for the inbuilt selectivity RTG/EZG has for potassium channels other than the KCNQ cardiac channel. KCNQ channels are active at the normal cell resting membrane potential (RMP) and contribute a continual hyperpolarizing influence that stabilizes cellular excitability. The MoA of RTG/EZG increases the number of KCNQ channels that are open at rest and also primes the cell to retort with a larger, more rapid, and more prolonged response to membrane depolarization or increased neuronal excitability. In this way, RTG/EZG amplifies this natural inhibitory force in the brain, acting like a brake to prevent the high levels of neuronal action potential burst firing (epileptiform activity) that may accompany sustained depolarizations associated with the initiation and propagation of seizures. This action to restore physiologic levels of neuronal activity is thought to underlie the efficacy of RTG/EZG as an anticonvulsant in a broad spectrum of preclinical seizure models and in placebo‐controlled trials in patients with partial epilepsy. In this article, we consider the pharmacologic characteristics of RTG/EZG at the receptor, cellular, and network levels as a means of understanding the novel and efficacious MoA of this new AED as defined in both preclinical and clinical research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Kwan, P., Arzimanoglou, A., Berg, A. T., Brodie, M. J., Allen Hauser, W., Mathern, G., Moshé, S. L., Perucca, E., Wiebe, S., & French, J. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02397.x · Cited by 4,877
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns
Singh, N. A., Charlier, C., Stauffer, D., DuPont, B. R., Leach, R. J., Melis, R., Ronen, G. M., Bjerre, I., Quattlebaum, T., Murphy, J. V., et al. (1998) · Nature Genetics · doi:10.1038/ng0198-25 · Cited by 1,199 · cited 4×
“, 2008)—that was found to be genetically linked to a form of inherited human epilepsy known as benign familial neonatal convulsions (BFNC) (Biervert et al., 1998; Charlier et al., 1998; Singh et al., 1998).”
BackgroundInfluentialA Potassium Channel Mutation in Neonatal Human Epilepsy
Biervert, C., Schroeder, B. C., Kubisch, C., Berkovic, S. F., Propping, P., Jentsch, T. J., & Steinlein, O. K. (1998) · Science · doi:10.1126/science.279.5349.403 · Cited by 1,073 · cited 4×
“, 2008)—that was found to be genetically linked to a form of inherited human epilepsy known as benign familial neonatal convulsions (BFNC) (Biervert et al., 1998; Charlier et al., 1998; Singh et al., 1998).”
BackgroundInfluentialA pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family
Charlier, C., Singh, N. A., Ryan, S. G., Lewis, T. B., Reus, B. E., Leach, R. J., & Leppert, M. (1998) · Nature Genetics · doi:10.1038/ng0198-53 · Cited by 937
Neuronal KCNQ potassium channels:physislogy and role in disease
Jentsch, T. J. (2000) · Nature Reviews Neuroscience · doi:10.1038/35036198 · Cited by 849
Brown, D. A., & Passmore, G. M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00111.x · Cited by 676 · cited 1×
“…understanding of the role of KCNQ channels in the control of neuronal excitability (Gribkoff, 2003; Surti & Jan, 2005; Maljevic et al., 2008; Brown & Passmore, 2009) that provides a rigorous foundation from which to interpret the broad anticonvulsant efficacy of RTG/EZG defined in…”
BackgroundPan, Z., Kao, T., Horvath, Z., Lemos, J., Sul, J.-Y., Cranstoun, S. D., Bennett, V., Scherer, S. S., & Cooper, E. C. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4314-05.2006 · Cited by 585
Potassium Channels: Molecular Defects, Diseases, and Therapeutic Opportunities
Shieh, C.-C., Coghlan, M., Sullivan, J. P., & Gopalakrishnan, M. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01469-8 · Cited by 518
Guide to Receptors and Channels (GRAC), 3rd edition
Alexander, S. P. H., Mathie, A., & Peters, J. A. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707746 · Cited by 510
Molecular Targets for Antiepileptic Drug Development
Meldrum, B. S., & Rogawski, M. A. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.11.010 · Cited by 468
Devaux, J. J., Kleopa, K. A., Cooper, E. C., & Scherer, S. S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4512-03.2004 · Cited by 450
Tatulian, L., Delmas, P., Abogadie, F. C., & Brown, D. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-15-05535.2001 · Cited by 406
Kharkovets, T., Hardelin, J.-P., Safieddine, S., Schweizer, M., El-Amraoui, A., Petit, C., & Jentsch, T. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4333 · Cited by 399
KCNQ/M Channels Control Spike Afterdepolarization and Burst Generation in Hippocampal Neurons
Yue, C., & Yaari, Y. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0765-04.2004 · Cited by 369
Gu, N., Vervaeke, K., Hu, H., & Storm, J. F. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.086835 · Cited by 363 · cited 2×
“…activity by RTG/ EZG is in line with the primary contribution of KCNQ channels to the medium afterhyperpolarization (mAHP), an observed conductance event that serves to control the excitability of neurones over a timescale in the order of tens to hundreds of ms (Storm, 1989; Gu et al., 2005).”
BackgroundRetigabine, A Novel Anti-Convulsant, Enhances Activation of KCNQ2/Q3 Potassium Channels
Wickenden, A. D., Yu, W., Zou, A., Jegla, T., & Wagoner, P. K. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12425-x · Cited by 320
An after‐hyperpolarization of medium duration in rat hippocampal pyramidal cells.
Storm, J. F. (1989) · The Journal of Physiology · doi:10.1113/jphysiol.1989.sp017491 · Cited by 319
Modulation of KCNQ2/3 Potassium Channels by the Novel Anticonvulsant Retigabine
Main, M. J., Cryan, J. E., Dupere, J. R. B., Cox, B., Clare, J. J., & Burbidge, S. A. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12060-3 · Cited by 299
Lerche, C., Scherer, C. R., Seebohm, G., Derst, C., Wei, A. D., Busch, A. E., & Steinmeyer, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002378200 · Cited by 277
Molecular Determinants of KCNQ (Kv7) K+Channel Sensitivity to the Anticonvulsant Retigabine
Schenzer, A., Friedrich, T., Pusch, M., Saftig, P., Jentsch, T. J., Grötzinger, J., & Schwake, M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0128-05.2005 · Cited by 267
Wuttke, T. V., Seebohm, G., Bail, S., Maljevic, S., & Lerche, H. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.010793 · Cited by 262
Mice with altered KCNQ4 K+ channels implicate sensory outer hair cells in human progressive deafness
Kharkovets, T., Dedek, K., Maier, H., Schweizer, M., Khimich, D., Nouvian, R., Vardanyan, V., Leuwer, R., Moser, T., & Jentsch, T. J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7600951 · Cited by 256
Rundfeldt, C., & Netzer, R. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00866-1 · Cited by 242
D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures
Rostock, A., Tober, C., Rundfeldt, C., Bartsch, R., Engel, J., Polymeropoulos, E. E., Kutscher, B., Löscher, W., Hönack, D., White, H. S., et al. (1996) · Epilepsy Research · doi:10.1016/0920-1211(95)00101-8 · Cited by 240
Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy
Brodie, M. J., Lerche, H., Gil-Nagel, A., Elger, C., Hall, S., Shin, P., Nohria, V., Mansbach, H., & On behalf of the RESTORE 2 Study Group (2010) · Neurology · doi:10.1212/wnl.0b013e3181fd6170 · Cited by 192
Chung, H. J., Jan, Y. N., & Jan, L. Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603376103 · Cited by 190
Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy
French, J. A., Abou-Khalil, B. W., Leroy, R. F., Yacubian, E. M. T., Shin, P., Hall, S., Mansbach, H., & Nohria, V. (2011) · Neurology · doi:10.1212/wnl.0b013e3182194bd3 · Cited by 186
Disruption of the Epilepsy KCNQ2 Gene Results in Neural Hyperexcitability
Watanabe, H., Nagata, E., Kosakai, A., Nakamura, M., Yokoyama, M., Tanaka, K., & Sasai, H. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750028.x · Cited by 182
Towards a structural view of gating in potassium channels
Swartz, K. J. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1559 · Cited by 177
The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells
Rundfeldt, C. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01249-1 · Cited by 173
Nervous system KV7 disorders: breakdown of a subthreshold brake
Maljevic, S., Wuttke, T. V., & Lerche, H. (2008) · The Journal of Physiology · doi:10.1113/jphysiol.2008.150656 · Cited by 160
GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence?
Wafford, K. A. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.006 · Cited by 154
Disruption of the epilepsy KCNQ2 gene results in neural hyperexcitability
Watanabe, H. (2000) · Neuroscience Research · doi:10.1016/s0168-0102(00)81544-8 · Cited by 148
D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures
Tober, C., Rostock, A., Rundfeldt, C., & Bartsch, R. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00073-8 · Cited by 139
Lange, W., Geißendörfer, J. K., Schenzer, A., Grötzinger, J., Seebohm, G., Friedrich, T., & Schwake, M. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.052282 · Cited by 132
Rundfeldt, C., & Netzer, R. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1300346 · Cited by 118
Tatulian, L., & Brown, D. A. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.039842 · Cited by 113
Otto, J. F., Kimball, M. M., & Wilcox, K. S. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.4.921 · Cited by 109
Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells
Wickenden, A. D., Zou, A., Wagoner, P. K., & Jegla, T. J. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703861 · Cited by 97
Lerche, C. J., Bruhova, I., Lerche, H., Steinmeyer, K., Wei, A. D., Strutz‐Seebohm, N., Lang, F. J. W., Busch, A. E., Zhorov, B. S., & Seebohm, G. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.031682 · Cited by 92
Molecular Determinants of KCNQ1 Channel Block by a Benzodiazepine
Seebohm, G., Chen, J., Strutz, N., Culberson, C., Lerche, C. J., & Sanguinetti, M. C. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.1.70 · Cited by 85
The therapeutic potential of neuronal KCNQ channel modulators
Gribkoff, V. K. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.6.737 · Cited by 81
Large, C. H., Sokal, D. M., Nehlig, A., Gunthorpe, M. J., Sankar, R., Crean, C. S., VanLandingham, K., & White, H. S. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2011.03364.x · Cited by 78
Self-citationKapetanović, I. M., Yonekawa, W. D., & Kupferberg, H. J. (1995) · Epilepsy Research · doi:10.1016/0920-1211(95)00050-x · Cited by 76
Porter, R. J., Nohria, V., & Rundfeldt, C. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.11.012 · Cited by 74
Armand, V., Rundfeldt, C., & Heinemann, U. (1999) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00005320 · Cited by 53
Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells
Rundfeldt, C. (1999) · Epilepsy Research · doi:10.1016/s0920-1211(98)00131-4 · Cited by 50
Łuszczki, J. J., Wu, J. Z., Raszewski, G., & Czuczwar, S. J. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0349-9 · Cited by 42
Mazarati, A. M., Wu, J. Z., Shin, D. H., Kwon, Y. S., & Sankar, R. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01674.x · Cited by 42
Self-citationA potassium channel, the M-channel, as a therapeutic target.
Surti, T. S., & Jan, L. Y. (2005) · PubMed · Cited by 42
Effects of retigabine on rhythmic synchronous activity of human neocortical slices
Straub, H., Köhling, R., Höhling, J., Rundfeldt, C., Tuxhorn, I., Ebner, A., Wolf, P., Pannek, H. W., & Speckmann, E. ‐. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00193-0 · Cited by 36
Expression profile and characterisation of a truncated KCNQ5 splice variant
Yeung, S. Y. M., Lange, W., Schwake, M., & Greenwood, I. A. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.129 · Cited by 35
Tompson, D. J., Crean, C. S., Reeve, R., & Berry, N. S. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.06.012 · Cited by 13
Cited by
Mechanisms of action of currently used antiseizure drugs
Sills, G. J., & Rogawski, M. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107966 · Cited by 489
Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet
Rogawski, M. A., Löscher, W., & Rho, J. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022780 · Cited by 336
Smooth Muscle Ion Channels and Regulation of Vascular Tone in Resistance Arteries and Arterioles
Tykocki, N. R., Boerman, E. M., & Jackson, W. F. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c160011 · Cited by 335
Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies
Oyrer, J., Maljevic, S., Scheffer, I. E., Berkovic, S. F., Petrou, S., & Reid, C. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014456 · Cited by 315
Early and effective treatment of KCNQ 2 encephalopathy
Pisano, T., Numis, A. L., Heavin, S. B., Weckhuysen, S., Angriman, M., Suls, A., Podesta, B., Thibert, R. L., Shapiro, K. A., Guerrini, R., et al. (2015) · Epilepsia · doi:10.1111/epi.12984 · Cited by 301
Metadata
- Authors
- Gunthorpe, M. J., Large, C. H., & Sankar, R.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2012-01-05
- Volume
- 53
- Issue
- 3
- Pages
- 412-424
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1500064345
- Cited by
- 319
- References
- 55
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.